What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Lung cancer, Internal medicine, Oncology, Gefitinib and Cancer research.
His Lung cancer study integrates concerns from other disciplines, such as Cancer, KRAS, Adverse effect and Immunology.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Surgery, with regards to Clinical endpoint.
His Oncology research incorporates elements of Targeted therapy, Clinical trial and Immunotherapy.
Gregory J. Riely has included themes like T790M, EGFR inhibitors and Erlotinib in his Gefitinib study.
The study incorporates disciplines such as Mutation and Gene mutation in addition to Cancer research.
His most cited work include:
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2867 citations)
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Lung.
His Internal medicine study frequently draws connections to adjacent fields such as Pathology.
His Oncology study incorporates themes from KRAS, Clinical trial and Carcinoma.
His research in Lung cancer intersects with topics in Cancer, Adverse effect, Pharmacology and Surgery.
While the research belongs to areas of Cancer research, he spends his time largely on the problem of T790M, intersecting his research to questions surrounding EGFR inhibitors.
His work carried out in the field of Lung brings together such families of science as EGFR Tyrosine Kinase Inhibitors, Egfr mutation, Blockade, Targeted therapy and Immunotherapy.
He most often published in these fields:
- Internal medicine (63.56%)
- Oncology (59.45%)
- Lung cancer (50.41%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (63.56%)
- Lung cancer (50.41%)
- Oncology (59.45%)
In recent papers he was focusing on the following fields of study:
Gregory J. Riely focuses on Internal medicine, Lung cancer, Oncology, Cancer research and Lung.
His Cancer, Adverse effect, Crizotinib and Alectinib study in the realm of Internal medicine interacts with subjects such as Response Evaluation Criteria in Solid Tumors.
His research in the fields of Erlotinib and Colorectal cancer overlaps with other disciplines such as Oncogene Addiction.
The concepts of his Lung cancer study are interwoven with issues in Mutation, KRAS, Progression-free survival and Epidermal growth factor receptor.
His Oncology research includes themes of Immunotherapy, Clinical trial, Chemotherapy and Adenocarcinoma.
His Cancer research research incorporates themes from Mutant, non-small cell lung cancer, Exon, Drug resistance and Osimertinib.
Between 2017 and 2021, his most popular works were:
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (530 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Lung cancer, Internal medicine, Oncology, Cancer research and Cancer.
His biological study spans a wide range of topics, including Immune checkpoint, Adverse effect and Carcinoma.
His work on Crizotinib, Targeted therapy and Progression-free survival as part of general Internal medicine research is frequently linked to Text mining and Response Evaluation Criteria in Solid Tumors, thereby connecting diverse disciplines of science.
His studies deal with areas such as Stage iv, Guideline, Brain metastasis and Systemic therapy as well as Oncology.
His Cancer research research is multidisciplinary, incorporating elements of Cell, Blockade, Mutant, Lung and Kinase.
He has researched Cancer in several fields, including Mutation and DNA sequencing.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
